Researchers have been investigating glucagon-like peptide 1 (GLP-1) receptor co-agonists for their cardiac effects, as detailed in a recent report in Naunyn-Schmiedeberg’s Archives of Pharmacology. GLP-1 and its receptor agonists (GLP-1RAs) have gained attention for their role in insulin secretion, glucose control, and potential cardiovascular benefits. While earlier GLP-1RA therapies demonstrated a reduction in major cardiovascular events, ongoing studies are exploring the untapped potential and diverse cardiac effects of newer GLP-1 co-agonists, which target multiple receptors such as the glucagon receptor (GCGR) and glucose-dependent insulinotropic polypeptide receptor (GIPR).
Findings indicate that these co-agonists, like CT-388 and CT-868, may effectively reduce body weight and blood glucose levels while simultaneously influencing cardiac metrics, including heart rate and systolic blood pressure. However, there are concerns regarding their effects on cardiac contractility and possible arrhythmic implications, advising caution in their widespread application.
The relevance of this research extends to clinicians and policymakers, emphasizing the need for vigilant assessment of the cardiovascular outcomes associated with these new pharmacotherapies. As the field progresses, understanding the differences in response between murine and human models will be critical. Ongoing trials will provide essential data to guide future clinical practice, ultimately impacting the management of patients with type 2 diabetes and associated cardiovascular risks.
Source: www.news-medical.net
